Immune-Mediated Diseases

Johnson & Johnson will pay $850 million to acquire the biotechnology company Proteologix Inc., the company announced in a press release.

What should rheumatologists know about what we've learned about COVID-19 and long COVID in 2023? Hosted by Dr. Leonard Calabrese.

The FDA has granted breakthrough therapy designation for felzartamab, an investigational antibody to treat primary membranous nephropathy.

New data found COVID-19 mRNA vaccines were effective against hospitalization in U.S. veterans amid the delta surge, with an effectiveness rate similar to that before delta. A report on the data was the top story in rheumatology last week.

Patients with inflammatory bowel disease and other immune-mediated diseases who receive Janus kinase inhibitors may be at increased risk for herpes zoster infection, according to the results of a meta-analysis.

Patients with inflammatory bowel disease and other immune-mediate diseases treated with anti-TNF alpha who previously had cancer are not at greater risk for recurrent or new primary cancers, according to the results of a population-based study.